Latest News & Features
Americas
The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions. 25 February 2016
Americas
Counterfeiting poses one of the greatest threats to the pharmaceutical industry, but there are good reasons to believe that companies are tackling the problem head on. Stephen Ward of Pinkerton reports. 25 February 2016
Americas
Pharmaceutical company Codexis has sued a rival and its founder for allegedly stealing trade secrets and infringing up to ten patents. 24 February 2016
Americas
Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another. 24 February 2016
Americas
The US Court of Appeals for the First Circuit has revived claims that pay-for-delay settlements involving pharmaceutical company Warner Chilcott may be in breach of competition law, despite the deals not including cash payments. 23 February 2016
Americas
AstraZeneca has sued Innopharma over its attempt to market a generic version of breast cancer treatment drug Faslodex. 22 February 2016
Big Pharma
The English High Court has rejected Janssen Sciences’ request for a stay in its patent infringement and invalidity dispute with Eli Lilly. 19 February 2016
Europe
The IP landscape in Europe for the CRISPR gene-editing technology is very murky, making it difficult for potential licensees, says Catherine Coombes of HGF. 18 February 2016
Americas
The US Federal Trade Commission has waded into a competition dispute at the US Court of Appeals for the Federal Circuit centring on ‘reverse payment’ settlements. 18 February 2016
Americas
During nearly 30 years as a US Supreme Court justice, Antonin Scalia had the unenviable tasks of ruling on homosexuality, the right to carry hand guns, and abortion. Nevertheless, it was a mystery patent case that proved the most difficult. WIPR looks back at some of the most important IP cases of the past few years and how Scalia voted on them. 18 February 2016